Trastuzumab Deruxtecan Resistance via Loss of HER2 Expression and Binding
Wanyi Chen(Memorial Sloan Kettering Cancer Center), Sarat Chandarlapaty(Memorial Sloan Kettering Cancer Center)
Cited by 9
Related Papers
Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
|Oncogene|2016|430
KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function
|Oncogene|2018|149
HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway
|Nature Communications|2021|86
Mutant SF3B1 promotes AKT- and NF-κB–driven mammary tumorigenesis
|Journal of Clinical Investigation|2020|45